Literature DB >> 23583463

The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine.

Saideh Fakharzadeh1, Somayeh Kalanaky, Maryam Hafizi, Mohammad Mahdi Goya, Zahra Masoumi, Said Namaki, Nezhat Shakeri, Maryam Abbasi, Mehdi Mahdavi, Mohammad Hassan Nazaran.   

Abstract

Prevention of hepatitis B requires a vaccine that stimulates the humoral and cellular immune responses in a balanced manner, particularly those associated with Th1 and cytotoxic T cells. Alum adjuvant is currently used in the hepatitis B vaccine formulations but it lacks the efficiency of establishing such immune responses. Therefore, for accessing a suitable vaccine to prevent this fatal disease, it is essential to design and construct a new adjuvant which can overcome the limitations of the alum adjuvant and can stimulate a strong Th1 response as used along with it. In the present study, the adjuvant effect of Hep-c, the first nano-complex which was synthesized by nanochelating technology to improve the immunogenicity of the vaccine against hepatitis B, had been evaluated. Female Balb/c mice were divided into 7 groups and were injected with 10μg/ml of the hepatitis B vaccine and different doses of Hep-c for 3 times. Groups merely treated with the vaccine, Hep-c or phosphate buffered solution were used as control. Total specific antibody, IgG1, IgG2a, IgG2b, IgM, interleukin-4 (IL-4) and interferon-gamma (IFN-γ) levels were examined by the ELISA method. The proliferative response of the splenocytes was evaluated using bromodeoxyuridine assay. Results showed that immunization with hepatitis B vaccine and Hep-c increased the lymphocyte proliferation and specific IgM and IgG2a compared to the hepatitis B vaccine immunized group. Also, this nano-complex significantly increased the IFN-γ and IL-4 cytokine levels compared to the hepatitis B vaccine immunized group. Our findings show that Hep-c can not only preserve the alum capacity to effectively stimulate production of the antibodies but also cover its inefficiency in inducing Th1 response and prompting cellular immunity. Thus, by boosting the performance of the hepatitis B vaccine, it seemed that this nano-adjuvant has the suitable potential to be used in the commercial HBS vaccine formulation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23583463     DOI: 10.1016/j.vaccine.2013.03.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Prophylactic vaccinations in chronic kidney disease: Current status.

Authors:  Alicja E Grzegorzewska
Journal:  Hum Vaccin Immunother       Date:  2015-04-27       Impact factor: 3.452

Review 2.  Neonatal Vaccination: Challenges and Intervention Strategies.

Authors:  Matthew C Morris; Naveen Surendran
Journal:  Neonatology       Date:  2016-01-13       Impact factor: 4.035

Review 3.  Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy.

Authors:  Dede Sit; Bennur Esen; Ahmet Engin Atay; Hasan Kayabaşı
Journal:  World J Hepatol       Date:  2015-04-18

4.  TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.

Authors:  Somayeh Kalanaky; Maryam Hafizi; Sepideh Safari; Kazem Mousavizadeh; Mahboubeh Kabiri; Alireza Farsinejad; Saideh Fakharzadeh; Mohammad Hassan Nazaran
Journal:  Int J Hematol       Date:  2016-02-01       Impact factor: 2.490

5.  Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses.

Authors:  Mohammad Ali Savoji; Setareh Haghighat; Mina Mirzaee; Bahareh Golkaran; Rayhaneh Mirzaee; Behzad Esfandiari; Mehdi Mahdavi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

6.  BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo.

Authors:  Somayeh Kalanaky; Maryam Hafizi; Saideh Fakharzadeh; Mohammad Vasei; Ladan Langroudi; Ehsan Janzamin; Seyed Mahmoud Hashemi; Maryam Khayamzadeh; Masoud Soleimani; Mohammad Esmaeil Akbari; Mohammad Hassan Nazaran
Journal:  Drug Des Devel Ther       Date:  2015-12-30       Impact factor: 4.162

7.  Nanochelating based nanocomplex, GFc7, improves quality and quantity of human mesenchymal stem cells during in vitro expansion.

Authors:  Maryam Hafizi; Atena Hajarizadeh; Amir Atashi; Somayeh Kalanaky; Saideh Fakharzadeh; Zahra Masoumi; Mohammad Hassan Nazaran; Masoud Soleimani
Journal:  Stem Cell Res Ther       Date:  2015-11-23       Impact factor: 6.832

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.